[DOI] [PMC free article] [PubMed] [Google Scholar] 209.Sandoval DA, Bagnol D, Woods SC, DAlessio DA, Seeley RJ
p -value 0.0544]), and orforglipron (RR 16.1146 [95% CI 0.7796, 333.0789
When appetite decreases, nutrition has to work harder
10 The 505(b)(2) pathway provides a regulatory route to overcome technical hurdles including stability, palatability, and manufacturing consistency, allowing firms to focus on improving drug performance rather than starting from zero. FDA 505(b)(2) Trend Analysis, 2025 14 The goal here is Defensive Innovation. By creating a differentiated productperhaps an oral liquid for patients with dysphagia or a longer-acting injectablea firm can bypass the innovators patents while offering a value story that payers will actually reimburse
While these medications offer an alternative for some patients, they are not necessarily a replacement for CPAP therapy